Table 1.
Patients’ characteristics n (%)
| Characteristics | Categories | Data |
| Age (yr) | Median (range) | 64 (35-81) |
| Gender | Male | 25 (54) |
| Female | 21 (46) | |
| Stage | Locally advanced | 5 (11) |
| Metastatic | 41 (89) | |
| ECOG PS | 0 | 10 (22) |
| 1 | 26 (56) | |
| 2 | 9 (20) | |
| 3 | 1 (2) | |
| Basal CA 19-9 (U/mL) | Median (range) | 897 (1-49, 483) |
| Interval between symptoms and treatment (wk) | Median (range) | 12 (2-179) |
| Clinical benefit | Evaluable | 33 (75) |
| Not evaluable | 13 (25) | |
| Follow-up (wk) | Median (range) | 21.5 (2-91) |
| Number of administrations | Median (range) | 9 (1-29) |
PS: Performance status; ECOG: Eastern Cooperative Oncology Group; CA 19-9: Carbohydrate antigen 19-9.